4.3 Article

Drug-Induced Cholestasis

期刊

CLINICS IN LIVER DISEASE
卷 17, 期 4, 页码 519-+

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2013.07.015

关键词

Drugs; Cholestasis; Liver injury; Bile duct injury; Management

向作者/读者索取更多资源

Drug-induced cholestasis manifests as an acute self-limiting injury or as a chronic perpetuating injury, resulting in duct loss and cirrhosis. The number of drugs implicated in drug-induced cholestasis grows every year as new drugs are developed and approved. Other agents such as herbals, nutritional supplements, and complementary and alternative medicines are also reported to cause cholestatic liver injury. Recent literature on molecular transporters involved in bile transport has improved our understanding of patterns of drug-induced liver injury and the mechanisms of cholestasis. This article summarizes the probable offending drugs and the diagnosis and management of drug-induced cholestasis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
Article Gastroenterology & Hepatology

Autoimmune Hepatitis Pathophysiology

Zhou Yuming, Tang Ruqi, Merrill Eric Gershwin, Ma Xiong

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Primary Biliary Cholangitis Pathophysiology

Inbal Houri, Gideon M. Hirschfield

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Treatment of Primary Biliary Cholangitis including Transplantation

Yasameen Muzahim, Ali Wakil, Mehak Bassi, Nikolaos Pyrsopoulos

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Phenotypes of Primary Sclerosing Cholangitis and Differential Diagnosis

Brian H. Horwich, Douglas T. Dieterich

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Treatment of Autoimmune Hepatitis

Aparna Goel, Paul Kwo

Summary: The goal of autoimmune hepatitis treatment is achieving clinical and biochemical remission. Standard care involves induction treatment with corticosteroids and gradual tapering of steroids. Alternatives to standard therapy can be considered for patients with intolerance or inadequate response. Treatment withdrawal is achievable in less than 20% of patients after 2 years of sustained remission, and liver transplantation should be considered for patients with progressive disease or complications.

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Systemic Complications of Primary Biliary Cholangitis

Mariana Zapata, Hendrick Pagan-Torres, Marlyn J. Mayo

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Primary Sclerosing Cholangitis Epidemiology, Diagnosis, and Presentation

Aalam Sohal, Sanya Kayani, Kris Kowdley

Summary: Primary sclerosing cholangitis (PSC) is an immune-mediated liver disease characterized by inflammation and fibrosis of bile ducts. It is commonly associated with inflammatory bowel disease, especially ulcerative colitis. The natural history of the disease varies among patients, but most will develop cirrhosis.

CLINICS IN LIVER DISEASE (2024)